{"product_id":"is-watch-and-wait-always-safe-for-small-thyroid-cancers-new-study-raises-important-concerns","title":"Is \"Watch and Wait\" Always Safe for Small Thyroid Cancers? New Study Raises Important Concerns","description":"\u003cp\u003eResearchers in Rome, Italy studied 203 patients with small papillary thyroid cancers (≤1 cm) to determine whether conservative, non-surgical treatment is always safe for these so-called \"low-risk\" tumors. They found that 37.4% of patients had hidden lymph node metastases that were not visible on preoperative ultrasound, and nearly three-quarters (72.4%) had at least one biological aggressive feature that could affect prognosis. Younger age and multifocality (multiple tumor foci) were identified as independent risk factors for lymph node involvement. The authors conclude that non-surgical management should be considered with caution, especially in younger patients, to avoid undertreatment.\u003c\/p\u003e\n\n\u003ch1\u003eIs \"Watch and Wait\" Always Safe for Small Thyroid Cancers? New Study Raises Important Concerns\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#background\"\u003eBackground: Why This Research Matters\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#methods\"\u003eStudy Methods: How the Research Was Conducted\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#findings\"\u003eKey Findings: Hidden Lymph Node Metastases and Aggressive Features\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#risk-factors\"\u003eRisk Factors: Which Patients Are Most Vulnerable?\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#surgical-implications\"\u003eSurgical Implications: How Frozen Section Examination Changed Treatment\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#complications\"\u003eComplications and Follow-Up\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#clinical-implications\"\u003eClinical Implications: What This Means for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eLimitations: What This Study Couldn't Prove\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations: What Patients Should Consider\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eIn 203 patients with small papillary thyroid cancers, 37.4% had hidden lymph node metastases despite negative ultrasound.\u003c\/li\u003e\n\u003cli\u003eOnly 27.6% of these patients had no biological aggressive features; 72.4% had at least one such feature.\u003c\/li\u003e\n\u003cli\u003eFrozen section examination during surgery changed the extent of surgery in 22.9% of patients.\u003c\/li\u003e\n\u003cli\u003eNo residual or recurrent disease was observed during median follow-up of 34 months after surgery.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eBackground: Why This Research Matters\u003c\/h2\u003e\n\n\u003cp\u003eOver the past few decades, doctors have observed a steady increase in the diagnosis of differentiated thyroid cancer, particularly papillary thyroid carcinoma (PTC) — the most common type of thyroid cancer. When these tumors measure 1 centimeter (about 0.4 inches) or less, they are called papillary thyroid microcarcinomas, or PTMCs.\u003c\/p\u003e\n\n\u003cp\u003eBecause PTMCs tend to grow slowly and often follow a relatively harmless course, many medical guidelines have shifted toward less aggressive treatment approaches. The 2015 American Thyroid Association (ATA) guidelines, for instance, suggest that thyroid lobectomy (removing only half of the thyroid gland) or even active surveillance (monitoring the tumor without surgery) may be appropriate for low-risk PTMCs, provided there are no detectable lymph node metastases or other biological aggressive features.\u003c\/p\u003e\n\n\u003cp\u003eHowever, this study challenges a critical assumption: that a small, seemingly isolated tumor is always harmless. The researchers point out that while recurrence rates for PTMCs are relatively low, and most studies show that patients under active surveillance do not experience significant short-term harm, PTMC is \"not completely innocuous.\" One striking statistic cited in the paper: delaying treatment of differentiated thyroid cancer for at least 12 months may increase the likelihood of cancer-related death by \u003cstrong\u003e130%\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eThe incidence of lymph node metastases (LNMs) in clinically node-negative (cN0) PTMCs — meaning no enlarged or abnormal lymph nodes were detected on examination or imaging — has been reported in up to \u003cstrong\u003e42% of cases\u003c\/strong\u003e in various studies. This is a remarkably high number for a disease often described as \"indolent\" (slow-growing and inactive).\u003c\/p\u003e\n\n\u003cp\u003eCurrently, no well-defined preoperative clinical parameter can reliably predict whether a patient with clinically unifocal (single-focus) cN0 PTC actually has hidden central lymph node metastases. Central neck lymph nodes are those located in the front of the neck, near the thyroid gland itself.\u003c\/p\u003e\n\n\u003cp\u003eThe researchers also note that central neck lymph node metastases are increasingly recognized as a potential marker of aggressive biological behavior and a risk factor for recurrence, distant metastases, reduced survival, and higher morbidity. This makes the question of how to manage these small tumors critically important.\u003c\/p\u003e\n\n\u003ch2 id=\"methods\"\u003eStudy Methods: How the Research Was Conducted\u003c\/h2\u003e\n\n\u003cp\u003eThe study was conducted at the Fondazione Policlinico Universitario Agostino Gemelli IRCCS in Rome, Italy, a national referral center for endocrine surgery. Between September 2014 and September 2023, a total of \u003cstrong\u003e4,216 thyroidectomies\u003c\/strong\u003e (surgical removal of the thyroid gland) were performed for malignancy at this center.\u003c\/p\u003e\n\n\u003cp\u003eFrom this large group, the researchers identified \u003cstrong\u003e203 patients (4.8%)\u003c\/strong\u003e who met all of the following inclusion criteria:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eAdult patients (18 years or older)\u003c\/li\u003e\n  \u003cli\u003eClassic papillary thyroid carcinoma or its subtypes\u003c\/li\u003e\n  \u003cli\u003eClinically unifocal (single tumor focus) and intrathyroidal (confined within the thyroid gland)\u003c\/li\u003e\n  \u003cli\u003eClinical tumor size ≤1 cm\u003c\/li\u003e\n  \u003cli\u003eClinically node-negative (cN0) — no evidence of lymph node spread\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003ePatients were excluded if they had prior head or neck radiation exposure, a family history of thyroid carcinoma, clinical evidence of multifocality (multiple tumor foci), evidence of lymph node metastases, or less than 6 months of follow-up.\u003c\/p\u003e\n\n\u003cp\u003eAll patients underwent \u003cstrong\u003ethyroid lobectomy (TL) plus ipsilateral central neck dissection (i-CND)\u003c\/strong\u003e as the first step of the surgical procedure. Thyroid lobectomy removes one half of the thyroid gland. Ipsilateral central neck dissection removes the lymph nodes on the same side of the neck as the tumor, in the central compartment (the area directly surrounding the thyroid).\u003c\/p\u003e\n\n\u003cp\u003eA key part of the study design involved \u003cstrong\u003efrozen section examination (FSE)\u003c\/strong\u003e. During surgery, the removed lymph nodes were immediately sent to a pathologist, who examined them under a microscope while the patient was still on the operating table. This \"frozen section\" technique provides rapid results within minutes, allowing the surgeon to make real-time decisions.\u003c\/p\u003e\n\n\u003cp\u003eWhen occult (hidden) ipsilateral lymph node metastases were found on FSE, the surgical team proceeded with \u003cstrong\u003ecompletion thyroidectomy (CT)\u003c\/strong\u003e — removing the remaining half of the thyroid — plus completion central neck dissection during the same operation. Additionally, following discussion at a multidisciplinary tumor board (MTB), patients with biological aggressive features identified on final pathology, or those who preferred more extensive surgery, were offered completion thyroidectomy within 6 months of the initial operation.\u003c\/p\u003e\n\n\u003cp\u003eFor each patient, the researchers recorded demographic data (age, sex), perioperative information (surgical details, complications), and follow-up data. The follow-up period ended on April 30, 2024. All data were collected retrospectively from a prospectively designed database for endocrine neoplasms, and the study was approved by the Ethical Committee of the center (ID 6584).\u003c\/p\u003e\n\n\u003cp\u003eThe researchers defined \"biological aggressive features\" to include:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eLymph node metastases (LNMs)\u003c\/li\u003e\n  \u003cli\u003eExtranodal extension (cancer spreading beyond the lymph node capsule)\u003c\/li\u003e\n  \u003cli\u003eAggressive histology subtypes (tumor variants known to behave more aggressively)\u003c\/li\u003e\n  \u003cli\u003eLymphovascular invasion (LVI — cancer cells invading blood or lymphatic vessels)\u003c\/li\u003e\n  \u003cli\u003eExtracapsular invasion (cancer spreading beyond the thyroid capsule)\u003c\/li\u003e\n  \u003cli\u003eMultifocality (multiple tumor foci within the thyroid)\u003c\/li\u003e\n  \u003cli\u003eBRAF-V600E mutation (a specific genetic mutation in the tumor)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eTumors were classified as aggressive histological variants if they had an aggressive subtype comprising ≥30% of the tumor, or if they were infiltrative follicular variants. Micrometastases were defined as lymph node deposits ≤2 mm, and macrometastases as those \u0026gt;2 mm.\u003c\/p\u003e\n\n\u003cp\u003eStatistical analysis was performed using receiver operating characteristic (ROC) curve analysis to assess the correlation between age and lymph node metastases. The Youden index was used to calculate the cutoff values with the best sensitivity and specificity. Univariable and multivariable analyses were used to determine the odds ratios for pathological nodal status (pN status). A significance level of ≤0.05 was considered statistically significant. All analyses were performed using the open-source statistical software R (version 4.3.2).\u003c\/p\u003e\n\n\u003ch2 id=\"findings\"\u003eKey Findings: Hidden Lymph Node Metastases and Aggressive Features\u003c\/h2\u003e\n\n\u003cp\u003eThe study's most striking finding is the high rate of occult (hidden) lymph node metastases in patients who were thought to have low-risk, node-negative disease. At final histopathological examination, \u003cstrong\u003e76 out of 203 patients (37.4%) were staged pN1a\u003c\/strong\u003e — meaning cancer was found in the central neck lymph nodes. Of these, 37 patients had only micrometastases (cancer deposits ≤2 mm).\u003c\/p\u003e\n\n\u003cp\u003eExtranodal extension — a sign of more aggressive disease where cancer cells have broken through the lymph node capsule — was detected in \u003cstrong\u003e5 patients (6.6%)\u003c\/strong\u003e of the 76 patients with lymph node involvement.\u003c\/p\u003e\n\n\u003cp\u003eThe rates of other biological aggressive features found on final histology were equally notable:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMultifocality\u003c\/strong\u003e (multiple tumor foci): 69 patients (34.0%)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLymphovascular invasion\u003c\/strong\u003e (LVI — cancer cells in blood or lymphatic vessels): 93 patients (45.8%)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eExtracapsular invasion\u003c\/strong\u003e (cancer beyond the thyroid capsule): 3 patients (1.5%)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAggressive subtypes\u003c\/strong\u003e: 30 patients (14.8%) — including 21 infiltrative follicular variant PTCs, 8 tall cell PTCs, and 1 solid\/trabecular PTC\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBRAF-V600E mutation\u003c\/strong\u003e: 7 patients (3.5%)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003ePerhaps most concerning: \u003cstrong\u003eonly 56 patients (27.6%) had NO aggressive biological features\u003c\/strong\u003e at all. This means that nearly three-quarters of these \"low-risk\" patients (72.4%) had at least one feature that could potentially affect their prognosis.\u003c\/p\u003e\n\n\u003cp\u003eAmong the 97 patients with classic PTC, 8 had follicular variant PTC, and 67 had PTCs with subtypes comprising less than 30% of the tumor.\u003c\/p\u003e\n\n\u003cp\u003eOf the 43 patients who underwent total thyroidectomy plus bilateral central neck dissection (b-CND) during the same operation due to occult lymph node metastases found on FSE, final histology revealed:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBilateral multifocality\u003c\/strong\u003e (tumor foci on both sides of the thyroid): 11 patients\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBilateral central lymph node metastases\u003c\/strong\u003e (cancer on both sides of the neck): 17 patients\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThese findings are particularly important because they show that cancer was not just on the side of the original tumor — it had already spread to the opposite side of the neck in a substantial number of patients.\u003c\/p\u003e\n\n\u003cp\u003eAdditionally, 20 patients underwent delayed completion thyroidectomy after multidisciplinary tumor board discussion. In this group, final histology showed contralateral (opposite-side) PTC foci in 6 cases and contralateral lymph node metastases in 3 cases.\u003c\/p\u003e\n\n\u003ch2 id=\"risk-factors\"\u003eRisk Factors: Which Patients Are Most Vulnerable?\u003c\/h2\u003e\n\n\u003cp\u003eThe researchers performed a detailed comparative analysis between patients with no lymph node metastases (pN0, 127 patients) and those with central lymph node metastases (pN1a, 76 patients) to identify risk factors for occult central lymph node involvement.\u003c\/p\u003e\n\n\u003cp\u003eOn univariable analysis (which examines each factor individually), three factors were statistically significantly associated with lymph node metastases:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eYounger age\u003c\/strong\u003e (p \u0026lt; 0.001) — patients with lymph node metastases were younger on average (mean 37.5 years) compared to those without (mean 43.9 years)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLymphovascular invasion\u003c\/strong\u003e (p = 0.037) — patients with LVI had an odds ratio of 1.84 (95% CI: 1.04–3.29) for lymph node involvement\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMultifocality\u003c\/strong\u003e (p \u0026lt; 0.001) — patients with multifocal disease had an odds ratio of 4.58 (95% CI: 2.48–8.61) for lymph node involvement\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eAfter multivariable logistic regression analysis (which accounts for all factors simultaneously), two factors were confirmed as \u003cstrong\u003eindependent risk factors\u003c\/strong\u003e for nodal involvement:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAge\u003c\/strong\u003e (p \u0026lt; 0.001) — with an odds ratio of 0.94 (95% CI: 0.92–0.97), meaning that for each additional year of age, the risk of lymph node metastasis decreases by about 6%\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMultifocality\u003c\/strong\u003e (p \u0026lt; 0.001) — with an odds ratio of 4.44 (95% CI: 2.23–9.12), meaning patients with multifocal disease were more than 4 times more likely to have lymph node metastases\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe researchers used ROC curve analysis to determine the relationship between age and lymph node metastases. The area under the curve (AUC) was 0.612 (p = 0.005), indicating a modest but statistically significant correlation. The optimal age cutoff was determined to be \u003cstrong\u003e35 years\u003c\/strong\u003e, with a sensitivity of 37.3% and a specificity of 82.9%. In plain terms: patients under 35 were more likely to have lymph node metastases, but age alone could not reliably predict who would or would not have nodal involvement. The authors emphasized that \u003cstrong\u003eno cutoff age could be identified beyond which nodal involvement could be safely excluded\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eInterestingly, the following factors were \u003cstrong\u003enot\u003c\/strong\u003e significantly associated with lymph node metastases in this study: sex (male vs. female), preoperative tumor size, postoperative tumor size, aggressive subtypes, extracapsular invasion, and BRAF-V600E mutation.\u003c\/p\u003e\n\n\u003cp\u003eThe researchers also compared patients with zero aggressive biological features (56 patients) versus those with one or more features (147 patients), but found no statistically significant differences in age, sex, or tumor size between these two groups. This underscores a crucial point: \u003cstrong\u003eno preoperative parameter could predict which patients would harbor aggressive biological features\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch2 id=\"surgical-implications\"\u003eSurgical Implications: How Frozen Section Examination Changed Treatment\u003c\/h2\u003e\n\n\u003cp\u003eA key innovation of this study is the routine use of frozen section examination (FSE) during surgery to evaluate lymph node status in real time. FSE was performed in 188 of the 203 patients (92.6%). In 15 patients (7.4%), FSE could not be performed due to the unavailability of the pathologist.\u003c\/p\u003e\n\n\u003cp\u003eThe results of FSE were striking:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eFSE identified occult central lymph node metastases in \u003cstrong\u003e46 out of 188 patients (24.5%)\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003e43 patients (22.9%) underwent total thyroidectomy plus bilateral central neck dissection during the same operation based on positive FSE results\u003c\/li\u003e\n  \u003cli\u003eIn 2 patients, FSE identified only 1 micrometastasis, and the first step (lobectomy plus i-CND) remained the final procedure\u003c\/li\u003e\n  \u003cli\u003eIn 1 patient, a macrometastasis was identified by FSE, but completion thyroidectomy was not performed due to loss of signal in the inferior laryngeal nerve during surgery (a complication that made further surgery riskier)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe accuracy of FSE was carefully evaluated:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFalse positive results\u003c\/strong\u003e (FSE said cancer was present but final pathology said no): 2 patients\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFalse negative results\u003c\/strong\u003e (FSE said no cancer but final pathology found cancer): 31 out of 142 patients (21.8%)\u003c\/li\u003e\n  \u003cli\u003eIn the cohort that did not receive FSE, 1 patient was staged pN1a after definitive histopathology\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eOverall, the FSE technique demonstrated a \u003cstrong\u003esensitivity of 78%, specificity of 95%, and accuracy of 82%\u003c\/strong\u003e in detecting occult lymph node metastases. This means FSE successfully identified 78% of patients who truly had lymph node metastases, correctly ruled out cancer in 95% of those who didn't have it, and gave the correct answer overall 82% of the time.\u003c\/p\u003e\n\n\u003cp\u003eMost importantly, the authors report that \u003cstrong\u003eFSE modified the extent of surgical dissection in 22.9% of patients\u003c\/strong\u003e. In other words, in nearly one in four patients, the real-time information from FSE led to a more extensive and potentially more effective operation than originally planned.\u003c\/p\u003e\n\n\u003cp\u003eThis intraoperative decision-making is crucial because the sensitivity of current ultrasound methods for detecting central compartment lymph node metastases ranges only from \u003cstrong\u003e23% to 53.2%\u003c\/strong\u003e — meaning more than half of central lymph node metastases are missed on preoperative imaging.\u003c\/p\u003e\n\n\u003cp\u003eThe authors also note that an adequate lymphadenectomy (lymph node removal) may ensure no residual lymph node metastases remain and reduce the need for secondary (second) surgery. This is a significant advantage, as reoperation on the neck carries higher risks of complications.\u003c\/p\u003e\n\n\u003ch2 id=\"complications\"\u003eComplications and Follow-Up\u003c\/h2\u003e\n\n\u003cp\u003eBecause 63 patients (31%) underwent either immediate completion thyroidectomy during the same operation or delayed completion thyroidectomy, the researchers carefully tracked surgical complications in this group.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eComplications related to the parathyroid glands\u003c\/strong\u003e (which control calcium levels) included:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTransient hypoparathyroidism\u003c\/strong\u003e (temporary low parathyroid hormone, causing low calcium): 20 patients (31.7%)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePermanent hypoparathyroidism\u003c\/strong\u003e (permanent low parathyroid hormone): 4 patients (6.3%)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eComplications related to the inferior laryngeal nerve\u003c\/strong\u003e (which controls the vocal cords) included:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTransient nerve palsy\u003c\/strong\u003e (temporary vocal cord weakness): 18 cases (6.8%) out of 266 nerves at risk\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePermanent nerve palsy\u003c\/strong\u003e (permanent vocal cord paralysis): 2 cases (0.7%) out of 266 nerves at risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eNo other complications were recorded. The authors acknowledge that their reported hypoparathyroidism rates (31.7% transient and 6.3% permanent) are relatively high, but they argue that in this selected population, the central neck dissection should be considered \u003cstrong\u003etherapeutic rather than prophylactic\u003c\/strong\u003e — because proven lymph node metastases were present. They note that their complication rates are in line with data reported after total thyroidectomy plus therapeutic central neck dissection in other studies. A meta-analysis by Wang et al. showed comparable ranges: 0%–9.8% transient nerve palsy, 0.4%–4.0% permanent nerve palsy, 7.4%–68.9% transient hypoparathyroidism, and 0%–8.1% permanent hypoparathyroidism.\u003c\/p\u003e\n\n\u003cp\u003eRegarding adjuvant treatment, \u003cstrong\u003eradioactive iodine (RAI) therapy was administered to 34 patients (53.9%)\u003c\/strong\u003e among those who underwent immediate or delayed completion thyroidectomy — 24 who had immediate completion plus bilateral CND and 10 who had delayed completion.\u003c\/p\u003e\n\n\u003cp\u003eThe follow-up period was completed for all patients, with a median duration of \u003cstrong\u003e34 months (interquartile range: 17–54 months)\u003c\/strong\u003e. Importantly, \u003cstrong\u003eno residual or recurrent disease was observed\u003c\/strong\u003e in any patient during the follow-up period.\u003c\/p\u003e\n\n\u003ch2 id=\"clinical-implications\"\u003eClinical Implications: What This Means for Patients\u003c\/h2\u003e\n\n\u003cp\u003eThis study challenges the widespread assumption that unifocal cN0 PTMC (a single small thyroid cancer with no detectable lymph node spread) always represents an indolent (harmless) disease. The findings have several important implications for patients and their doctors.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eFirst, hidden lymph node metastases are common.\u003c\/strong\u003e More than one-third of patients (37.4%) who were told they had \"node-negative\" disease actually had cancer in their central neck lymph nodes when those nodes were surgically removed and examined under a microscope. This rate is consistent with other studies that have reported central lymph node metastases in up to 42% of PTMC patients despite negative preoperative imaging.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eSecond, \"low-risk\" does not mean \"no-risk.\"\u003c\/strong\u003e Only 27.6% of patients in this study were completely free of biological aggressive features after pathological evaluation. Nearly three-quarters had at least one feature — such as lymphovascular invasion, multifocality, aggressive tumor subtypes, or BRAF mutations — that could influence their long-term outlook.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eThird, younger patients are at higher risk.\u003c\/strong\u003e The study found that age was an independent risk factor for lymph node metastases, with patients under 35 years being at particularly increased risk. This is especially relevant because active surveillance and other conservative strategies are often proposed for younger patients, who have the longest remaining lifespan to potentially be harmed by undertreatment.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eFourth, preoperative imaging is not enough.\u003c\/strong\u003e Current ultrasound methods miss the majority of central lymph node metastases (sensitivity of only 23%–53.2%). This means that a \"clean\" ultrasound cannot reliably confirm that a patient is truly node-negative.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eFifth, real-time surgical assessment can change treatment.\u003c\/strong\u003e The use of frozen section examination during surgery allowed the surgical team to identify hidden lymph node metastases in real time and expand the operation accordingly in 22.9% of patients. This approach enables more accurate risk stratification and therapeutic modulation — patients who need more extensive surgery can get it in a single operation, rather than requiring a second surgery later.\u003c\/p\u003e\n\n\u003cp\u003eThe authors emphasize that lymph node metastases are a potential marker of aggressive PTMC behavior and a risk factor for recurrence, distant metastases, reduced survival, and higher morbidity. The presence of bilateral central lymph node metastases (found in 17 of the 43 patients who underwent immediate total thyroidectomy) and extranodal extension (found in 5 patients) further underscores that even small thyroid cancers can behave aggressively.\u003c\/p\u003e\n\n\u003cp\u003eWhile some authors have advocated for active surveillance in patients with multifocal disease or isolated BRAF-V600E mutations, this study's findings support the opposing view that these factors may be high-risk features for nodal metastases and recurrence. Similarly, lymphovascular invasion has been identified as a risk factor for undertreatment in active surveillance because it cannot be detected without surgical pathology.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eLimitations: What This Study Couldn't Prove\u003c\/h2\u003e\n\n\u003cp\u003eThe authors acknowledge several limitations of their study that patients and clinicians should understand when interpreting the results.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRetrospective design.\u003c\/strong\u003e Although data were collected from a prospectively designed database, the study is retrospective in nature, which means it looks back at what happened rather than following patients forward from a predetermined starting point. This design cannot establish causation, only association.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eSingle-center experience.\u003c\/strong\u003e All patients were treated at one high-volume referral center in Rome, Italy, by experienced endocrine surgeons. The results may not be generalizable to lower-volume centers or different healthcare settings. The rate of lymph node metastases could be influenced by the center's surgical expertise and pathological evaluation protocols.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eNo comparison group.\u003c\/strong\u003e The study did not compare surgical outcomes against an active surveillance group or a thermal ablation group. Therefore, it cannot directly prove that surgery is superior to conservative management — it only demonstrates that the disease is more aggressive than previously assumed in a substantial proportion of patients.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eLimited follow-up.\u003c\/strong\u003e The median follow-up of 34 months (range 17–54 months) is relatively short for a slow-growing cancer like PTMC. Longer follow-up would be needed to demonstrate differences in recurrence or survival outcomes between treatment approaches.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eNo preoperative predictor identified.\u003c\/strong\u003e The study confirmed that no preoperative parameter could reliably predict the presence of lymph node metastases or biological aggressive features. Even the age cutoff of 35 years, while statistically significant, had only 37.3% sensitivity — meaning it missed 62.7% of patients with lymph node metastases.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eSelection bias.\u003c\/strong\u003e The study population was specifically those patients scheduled for lobectomy, which may not represent all PTMC patients. Additionally, the decision to perform completion thyroidectomy in some patients but not others could introduce bias.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eStatistical limitations.\u003c\/strong\u003e Some of the subgroup analyses involved small numbers of patients (e.g., only 3 patients with extracapsular invasion, 7 with BRAF-V600E mutation), which limits the statistical power to detect true differences in these subgroups.\u003c\/p\u003e\n\n\u003ch2 id=\"recommendations\"\u003eRecommendations: What Patients Should Consider\u003c\/h2\u003e\n\n\u003cp\u003eBased on this study's findings, the authors offer clear guidance that patients diagnosed with PTMC — and especially younger patients — should discuss carefully with their medical team. Here are the key takeaways and recommended discussion points:\u003c\/p\u003e\n\n\u003ch3\u003eFor patients considering active surveillance or non-surgical treatment:\u003c\/h3\u003e\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eUnderstand the limits of imaging.\u003c\/strong\u003e A negative ultrasound does not guarantee that lymph nodes are cancer-free. Ultrasound misses between 47% and 77% of central lymph node metastases.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eKnow your age risk.\u003c\/strong\u003e If you are under 35 years old, your risk of hidden lymph node metastases is significantly higher. Exercise particular caution before choosing conservative management.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk about multifocality.\u003c\/strong\u003e If your diagnostic evaluation suggests the possibility of multiple tumor foci (multifocality), your risk of lymph node involvement is more than four times higher. This should factor into your treatment decision.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRecognize the \"hidden features\" problem.\u003c\/strong\u003e Biological aggressive features like lymphovascular invasion, aggressive tumor subtypes, and BRAF mutations can only be detected after surgical removal and pathological examination. Non-surgical management, by definition, cannot reveal these features.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003ch3\u003eFor patients considering surgery:\u003c\/h3\u003e\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk about frozen section examination.\u003c\/strong\u003e If your surgeon offers intraoperative frozen section of removed lymph nodes, this can guide real-time surgical decisions and identify patients who benefit from more extensive surgery.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eConsider a single-stage approach.\u003c\/strong\u003e The study's protocol — lobectomy with ipsilateral central neck dissection as the first step, followed by completion thyroidectomy if positive nodes are found — allowed 22.9% of patients to receive the appropriate more extensive surgery in a single operation, avoiding a second surgery.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eChoose a high-volume center.\u003c\/strong\u003e The study was conducted at a national referral center with experienced endocrine surgeons. In high-volume centers, prophylactic central neck dissection is associated with both a lower number of local relapses and a low risk of complications, as reported in several recent meta-analyses.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eWeigh complication risks.\u003c\/strong\u003e Surgical complications — including transient hypoparathyroidism (31.7%) and permanent hypoparathyroidism (6.3%) — are real considerations. However, the authors argue that when lymph node metastases are found, the central neck dissection is therapeutic rather than prophylactic, and the complication rates are in line with those seen after therapeutic neck dissection for confirmed disease.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003ch3\u003eThe bottom line:\u003c\/h3\u003e\n\u003cp\u003eThe authors conclude that \"nonsurgical management should be considered with caution to avoid undertreatment especially in the younger population.\" While this study does not prove that every PTMC requires surgery, it does demonstrate that \"a non-negligible rate of patients may present one or more biologically aggressive features including nodal involvement.\" Patients should have an informed, shared decision-making discussion with their medical team that honestly addresses these risks.\u003c\/p\u003e\n\n\u003cp\u003eIt is also worth noting that no residual or recurrent disease was observed in any patient during follow-up (median 34 months), suggesting that the surgical approach used in this study — thyroid lobectomy plus central neck dissection with selective completion thyroidectomy — achieved excellent short-term oncological control in this patient population.\u003c\/p\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat are hidden lymph node metastases in small papillary thyroid cancer?\u003c\/h3\u003e\n\u003cp\u003eHidden lymph node metastases are cancer cells found in neck lymph nodes that did not show up on preoperative ultrasound. In one study of 203 patients with small thyroid cancers, 37.4% had such hidden central neck lymph node metastases when the nodes were surgically removed and examined under a microscope.\u003c\/p\u003e\n\u003ch3\u003eWhat is frozen section examination during thyroid surgery?\u003c\/h3\u003e\n\u003cp\u003eFrozen section examination is a rapid test done during surgery. Removed lymph nodes are sent to a pathologist who examines them under a microscope while the patient is still on the operating table. Results come back within minutes, allowing the surgeon to decide whether to remove more tissue in the same operation.\u003c\/p\u003e\n\u003ch3\u003eHow does age affect the risk of lymph node spread in small thyroid cancers?\u003c\/h3\u003e\n\u003cp\u003eIn a study of 203 patients with small papillary thyroid cancers, younger age was an independent risk factor for lymph node metastases. For each additional year of age, the risk decreased by about 6%. Patients under 35 years had a higher risk, but no age cutoff could safely exclude nodal involvement.\u003c\/p\u003e\n\u003ch3\u003eWhat does multifocality mean and how does it affect thyroid cancer risk?\u003c\/h3\u003e\n\u003cp\u003eMultifocality means there are multiple tumor foci within the thyroid gland. In a study of 203 patients with clinically single-focus small thyroid cancers, 34% were found to have multifocal disease on final pathology. Patients with multifocality were more than four times more likely to have hidden lymph node metastases.\u003c\/p\u003e\n\u003ch3\u003eWhat are the main complications after thyroid surgery with central neck dissection?\u003c\/h3\u003e\n\u003cp\u003eIn a study of 203 patients who had thyroid lobectomy plus central neck dissection, complications included temporary low parathyroid hormone in 20 of 63 patients who had completion surgery, permanent low parathyroid hormone in 4 patients, temporary vocal cord weakness in 18 cases, and permanent vocal cord paralysis in 2 cases out of 266 nerves at risk.\u003c\/p\u003e\n\u003ch3\u003eCan ultrasound reliably rule out lymph node spread in small thyroid cancers?\u003c\/h3\u003e\n\u003cp\u003eNo. Ultrasound misses many central lymph node metastases. The sensitivity of ultrasound for detecting central compartment lymph node metastases ranges from 23% to 53.2%. In one study, 37.4% of patients with negative ultrasound actually had lymph node metastases found after surgery, so a clean ultrasound cannot confirm that nodes are cancer-free.\u003c\/p\u003e\n\u003ch3\u003eWhat should younger patients with small thyroid cancers consider before choosing active surveillance?\u003c\/h3\u003e\n\u003cp\u003eYounger patients, especially those under 35, had a higher risk of hidden lymph node metastases in one study. Active surveillance cannot detect biological aggressive features that are only visible under a microscope after surgery. The study authors advise caution with nonsurgical management in younger patients to avoid undertreatment, and recommend discussing risks with your medical team.\u003c\/p\u003e\n\u003ch3\u003eMy doctor says my 1 cm papillary thyroid cancer can be watched without surgery. Should I get a second opinion before choosing active surveillance?\u003c\/h3\u003e\n\u003cp\u003eFor a small papillary thyroid cancer (≤1 cm) that appears single and node-negative on ultrasound, hidden lymph node metastases have been found in 37.4% of surgical patients, and 72.4% had at least one aggressive feature. Younger age (under 35) and multifocality increase nodal risk more than fourfold. Ultrasound misses most central lymph node metastases, so imaging cannot reliably exclude spread. A second opinion can help clarify whether your age, tumor features, and treatment options justify surgery over active surveillance. Diagnostic Detectives Network provides independent expert second opinions.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eOriginal Article Title:\u003c\/strong\u003e Is conservative treatment always safe in unifocal clinically T1a:node‐negative papillary thyroid carcinoma\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOI:\u003c\/strong\u003e \u003ca href=\"https:\/\/doi.org\/10.1002\/wjs.12440\" target=\"_blank\" rel=\"noopener\"\u003e10.1002\/wjs.12440\u003c\/a\u003e\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAuthors:\u003c\/strong\u003e Francesco Pennestrì, Priscilla Francesca Procopio, Antonio Laurino, Annamaria Martullo, Gloria Santoro, Pierpaolo Gallucci, Francesca Prioli, Luca Sessa, Esther Diana Rossi, Alfredo Pontecorvi, Carmela De Crea, and Marco Raffaelli\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eJournal:\u003c\/strong\u003e World Journal of Surgery, 2025; Volume 49, pages 187–197. DOI: 10.1002\/wjs.12440\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePublication Details:\u003c\/strong\u003e Received June 2, 2024; Accepted November 23, 2024. Published by John Wiley \u0026amp; Sons Ltd on behalf of the International Society of Surgery\/Société Internationale de Chirurgie (ISS\/SIC). This is an open access article under the terms of the Creative Commons Attribution License.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eStudy Setting:\u003c\/strong\u003e Fondazione Policlinico Universitario Agostino Gemelli IRCCS and Università Cattolica del Sacro Cuore, Rome, Italy.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAbstract Selection:\u003c\/strong\u003e The abstract of this manuscript was selected for the IAES Free Paper Session at the International Surgical Week ISW 2024 in Kuala Lumpur, Malaysia, August 25–29, 2024.\u003c\/p\u003e\n\n\u003cp\u003e\u003cem\u003eThis patient-friendly article is based on peer-reviewed research published in the World Journal of Surgery. It is intended for educational purposes and does not constitute medical advice. Patients should consult their healthcare providers for guidance specific to their individual medical situation.\u003c\/em\u003e\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47576624955548,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/diagnosticdetectives.com\/zh\/products\/is-watch-and-wait-always-safe-for-small-thyroid-cancers-new-study-raises-important-concerns","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}